SCHEMBL1133684

SCHEMBL1133684

O=Cc1ccc(-c2ccc(Br)cc2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.54
CYP2E1 P05181 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2A6 P11509 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2B6 P20813 1/20 0.51
CYP2C19 P33261 1/20 0.51
PRF1 P14222 2/20 0.51
MAPT P10636 2/20 0.46
DPP4 P27487 1/20 0.46
PGR P06401 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
PRKDC P78527 1/20 0.39
KDM4E B2RXH2 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9199395 0.82 CYP2E1 (0.54) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL2018262 0.80 APP (0.61) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL1133750 0.80 APP (0.54) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL7905308 0.80 APP (0.68) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL9538845 0.80 APP (0.54) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL1134019 0.80 APP (0.54) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL1133819 0.80 APP (0.54) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL70783 0.79 APP (0.67) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL3630228 0.78 APP (0.81) APPCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL278904 0.78 DPP4 (0.65) APPCYP2E1CYP3A4CYP2A6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435075-B2 Compound, film, sensor, and electronic device SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-10-07 US disclosed
EP-4174063-A1 COMPOUND, FILM, SENSOR, AND ELECTRONIC DEVICE Samsung Electronics Co., Ltd. (KR) 2023-05-03 EP disclosed
CN-116023369-A Compound, membrane, sensor and electronic device 三星电子株式会社 2023-04-28 CN disclosed
US-20230125778-A1 COMPOUND, FILM, SENSOR, AND ELECTRONIC DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-04-27 US disclosed
US-20230125778-A1 COMPOUND, FILM, SENSOR, AND ELECTRONIC DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-04-27 US disclosed
US-20230125778-A1 COMPOUND, FILM, SENSOR, AND ELECTRONIC DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-04-27 US disclosed
WO-2023011657-A1 METHOD FOR DETECTING AND QUANTIFYING RNA 纳莹(上海)生物科技有限公司 2023-02-09 WO disclosed
WO-2023011658-A1 METHOD FOR DETECTING AND QUANTIFYING RNA 纳莹(上海)生物科技有限公司 2023-02-09 WO disclosed
EP-2285802-B1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY ASTEX PHARMACEUTICALS INC (US) 2015-11-11 EP disclosed
US-8759384-B2 Oxo-imidazolyl compounds ASTEXPHRMACEUTICALS, INC. 2014-06-24 US disclosed
WO-2010081904-A1 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS GLAXO GROUP LIMITED (GB) 2010-07-22 WO disclosed
US-20100173891-A1 HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF HERBERT BRIAN 2010-07-08 US disclosed
US-7700630-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-20 US disclosed
US-20090298900-A1 Oxo-Imidazolyl Compounds ASTEXPHRMACEUTICALS, INC. 2009-12-03 US disclosed
WO-2009139870-A1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY SUPERGEN, INC. 2009-11-19 WO disclosed
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system HERBERT BRIAN 2009-04-23 US disclosed
US-7244745-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. (US) 2007-07-17 US disclosed
EP-1531820-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Memory Pharmaceuticals Corporation (US) 2005-05-25 EP disclosed
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. 2004-11-18 US disclosed
WO-2004019943-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MEMORY PHARMACEUTICALS CORPORATION (US) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125778-A1 COMPOUND, FILM, SENSOR, AND ELECTRONIC DEVICE HAX1, CYP19A1, ESR1 APP 586/4885CYP2E1 78/4885CYP3A4 481/4885
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof CHRNA1, CHRNA4, CHRNA3 APP 2223/4885CYP2E1 571/4885CYP3A4 273/4885
US-20090298900-A1 Oxo-Imidazolyl Compounds GALE, CYP51A1, GNE APP 4844/4885CYP2E1 91/4885CYP3A4 57/4885
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system CHRNA3, CHRNA2, CHRNA5 APP 157/4885CYP2E1 1327/4885CYP3A4 1139/4885
US-20100173891-A1 HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF CHRM3, CHRNA1, CHRNA5 APP 2290/4885CYP2E1 879/4885CYP3A4 367/4885
US-12435075-B2 Compound, film, sensor, and electronic device HAX1, CYP19A1, ESR1 APP 586/4885CYP2E1 78/4885CYP3A4 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.